Results for tag: "Tegsedi"

Tegsedi (inotersen) is a drug used to treat polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults. It is a small interfering ribonucleic acid (siRNA) molecule that works by targeting and silencing the transthyretin (TTR) gene, which is responsible for producing the abnormal TTR protein that causes hATTR amyloidosis. Tegsedi is administered as a subcutaneous injection and is the first and only approved therapy for hATTR amyloidosis. The Tegsedi market is a rapidly growing segment of the Central Nervous System (CNS) drugs market. It is expected to experience strong growth in the coming years due to the increasing prevalence of hATTR amyloidosis and the availability of effective treatments. The market is also expected to benefit from the increasing awareness of the disease and the availability of new treatments. Some of the major companies in the Tegsedi market include Ionis Pharmaceuticals, Akcea Therapeutics, Pfizer, and Novartis. Show Less Read more